Searched for
AUROBINDO PHARMA Q1 RESULTS
Ashok Leyland just had a record June quarter. So why did the margin fall a full point?Ashok Leyland's June-quarter has an unusual contradiction. The company sold 48,763 commercial vehicles, its highest-ever first-quarter volu...- RIL Q2 Results: Nuvama sees 17% EBITDA growth, led by O2C biz. Here’s what to expectReliance Industries is expected to report 17% year-on-year growth in Q2FY27 EBITDA to Rs 53,700 crore, led by stronger refining margins and...
- Stocks in news: Infosys, HDFC Bank, Jio Financial, IRFC, NCC and Blue DartIndian equity benchmarks experienced a decline over two sessions due to profit booking and rising oil prices. The Nifty 50 index closed dow...
- Q2 earnings: Can India Inc repeat Q1, or will Q3 erase the base-effect tailwind?India Inc is likely to see a dip in earnings performance for Q2 in comparison to Q1, with analysts forecasting a growth slowdown of roughly...
- TCS, Wipro, other IT stocks rebound up to 6%, snapping 8-day losing streak. Why is Jefferies cautious?IT stocks rebounded on Wednesday, with TCS, Wipro and Coforge snapping an eight-session losing streak. The Nifty IT index rose nearly 3%, a...
- SC seeks 16% MRP cap on medicines, flags huge cancer drug markupsThe Supreme Court has raised concerns regarding inflated prices of essential medicines, particularly cancer drugs, sold at exorbitant marku...
- Ahead of Market: 10 things that will decide stock market action on WednesdayNifty’s indicative price plunged 2% in two seconds during the closing auction session on monthly expiry, before recovering sharply. Analyst...
- Two Trades for Today: 2 mid-cap pharma stocks, one for a rise of 6.2%, and the other for a gain of almost 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platformAnupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...
- Honasa Consumer shares fall 5% after Rs 643 crore block deal; Peak XV, Sequoia likely sellersHonasa Consumer shares declined up to 5% after 1.4 crore shares worth Rs 643 crore changed hands in a block deal. The transaction comes aft...
- Auto stocks: Festive demand gets a low-base boost; can earnings justify valuations?The Indian automobile market is witnessing robust retail sales as the festive season draws near. A significant year-on-year uptick of 81.8%...
- Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugsIndian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% ...
- Goldman Sachs sees Eternal achieving $1 billion EBITDA by FY29; raises target priceGoldman Sachs maintained a Buy rating on Eternal, formerly Zomato, raising its target price by 11% to Rs 385. The brokerage foresees Eterna...
- Alaska has the shortest workweek in America, but it isn’t close to No. 1 for work-life balance; these US states are the best and worst for work-life balance in 2026Work-life balance: Remote’s 2025 Life-Work Balance Index compares all 50 states using factors such as average work hours, happiness, statut...
- Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers al...
- Suzlon Energy shares fall 2% to near six-month low, down 15% in one monthSuzlon Energy shares slipped over 2% to a near six-month low, approaching their 52-week low amid higher trading volumes and broader market ...
- Meesho shares can fall 28%, warns Nomura after initiating coverage with Reduce call. Here is whyShares of Meesho dropped up to 5% to Rs 221 after Nomura initiated coverage with a Reduce rating and a Rs 167 target price, citing a 28% do...
- Meesho shares rally 12% after UBS hikes target price by 24%. What’s keeping analysts bullish?UBS has raised its Meesho estimates across NMV, contribution profit and EBITDA, citing stronger seller and buyer growth and improving unit ...
- Decoding GDP growth: The good, the bad & the dataET drew up a longlist of more than five dozen indicators across all key themes of the economy— from the external sector and markets to farm...
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
Load More
